Declaration of interests NS has consulted for Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi, MSD, Novartis, Novo Nordisk, Pfizer, and Sanofi; and received grant support from Boehringer Ingelheim, outside the submitted work. MMYL's employer, the University of Glasgow, has received grant support from Boehringer Ingelheim. SLK reports speaker fees from AstraZeneca, outside the submitted work. KRHB reports research grant funding from Bayer, Sanofi, and Eli Lilly; and consultation fees from Amgen, Bayer, Janssen, Sana, and Kestra. RDL reports research grants and personal fees from Bristol-Myers Squibb and Pfizer; personal fees from Boehringer Ingelheim and Bayer; and research grants from Amgen, GlaxoSmithKline, Medtronic, and Sanofi Aventis, outside the submitted work. CSPL has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as consultant or on the advisory board, steering committee, or executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, Us2.ai, Janssen Research & Development, Medscape, MSD, Novartis, Novo Nordisk, Radcliffe Group, Roche Diagnostics, Sanofi, and WebMD Global; and serves as co-founder and non-executive director of Us2.ai. SDP consulted for Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Novo Nordisk, and Sanofi; received grant support from AstraZeneca and Boehringer Ingelheim; and speaker fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Novo Nordisk, and Sanofi. JJVM acknowledges payments to his employer, the University of Glasgow, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Theracos; personal lecture fees from Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Lupin, Sun Pharmaceuticals, Medscape/Heart.Org, ProAdWise Communications, Radcliffe Cardiology, Servier, and the Corpus. JR has participated in advisory panels for Boehringer Ingelheim, Intarcia Therapeutics, Applied Therapeutics, Eli Lilly, Hanmi, Novo Nordisk, Sanofi, Oramed, and Zealand Pharma; and has received research support from Applied Therapeutics, GlaxoSmithKline, Pfizer, Intarcia Therapeutics, Genentech, MSD, Eli Lilly, Novartis, Novo Nordisk, Sanofi, Hanmi, and Oramed. REP reports grants from Hanmi; grants from Janssen and Poxel SA; consulting fees from MSD, Scohia, and Sun Pharmaceutical Industries; grants, speaker fees, and consulting fees from Novo Nordisk; consulting fees from Pfizer; and grants and consulting fees from Sanofi. REP's services were paid for directly to AdventHealth, a non-profit organisation. HCG holds the McMaster-Sanofi Population Health Institute Chair in Diabetes Research and Care. He reports research grants from Eli Lilly, AstraZeneca, MSD, Novo Nordisk, and Sanofi; honoraria for speaking from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, DKSH, and Zuellig; and consulting fees from Abbott, Covance, Eli Lilly, Novo Nordisk, Sanofi, Pfizer, Kowa, and Hanmi.
PubMed
